Disc Medicine outlines recent pipeline, priorities for 2025

Disc Medicine (IRON) outlined its recent pipeline and operational progress and strategic priorities for 2025. Key Business Objectives and Milestones for 2025: Pursue development and global registration of bitopertin in erythropoietic protoporphyria, with the potential for accelerated approval in the U.S. using PPIX as surrogate endpoint: Provide update in Q1 2025 on design of confirmatory APOLLO trial and plans for NDA submission, following Type C meeting with FDA; Initiate global, confirmatory APOLLO trial by mid-2025; Obtain protocol assistance and feedback on regulatory path from EMA. Pursue next stage of development of DISC-0974 for the treatment of anemia in myelofibrosis patients and generate additional data supporting activity and dose selection in CKD anemia: Progress ongoing phase 2 MF anemia trial with initial data expected H2 2025, Progress ongoing phase 1b CKD anemia trial with multiple-dose data expected H2 2025, Continue to develop scientific rationale for hepcidin suppression in other anemias. Initiate phase 2 clinical trial of DISC-3405 in PV and broaden role of iron restriction in other indications: Plan to initiate phase 2 clinical trial of DISC-3405 in PV in H1 2025; Continued to develop scientific rationale for therapeutic iron restriction in sickle cell disease and other indications.